Condition: Gastroesophageal Adenocarcinoma · First Line Therapy · HER2 + Gastric Cancer · Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
The ZANGEA trial is a open-label, single arm, multicenter phase II trial assessing the efficacy of zanidatamab in combination with pembrolizumab and chemotherapy in patients with metastatic gastroesophageal adenocarcinoma (GEA). The patients need to be previously untreated in the palliative setting and tested positive for HER2 and PD-L1.
This description comes directly from the study's public registry record.
Alexander Stein, Prof. Dr. · +49 (0) 40 36035220 · stein@hope-hamburg.de
Clara Dreyling, Dr. · +49 (0)69 5899 787 31 · dreyling.clara@ikf-khnw.de
Always discuss trial participation with your own doctor first.
| Charité CVK | Berlin, Germany | Recruiting |
| Vivantes Klinikum im Friedrichshain | Berlin, Germany | Recruiting |
| Klinikum Bielefeld | Bielefeld, Germany | Recruiting |
| Städtisches Klinikum Dresden | Dresden, Germany | Not Yet Recruiting |
| Evang. Kliniken Essen Mitte | Essen, Germany | Recruiting |
| Krankenhaus Nordwest | Frankfurt, Germany | Recruiting |
| Universitätsklinikum Göttingen | Göttingen, Germany | Not Yet Recruiting |
| Hämatologisch Onkologische Praxis Eppendorf (HOPE) | Hamburg, Germany | Recruiting |
| Asklepios Klinik Altona | Hamburg, Germany | Recruiting |
| Universitätsklinikum Hamburg Eppendorf | Hamburg, Germany | Recruiting |
| St. Anna Hospital Herne | Herne, Germany | Recruiting |
| Universitätsklinikum Jena | Jena, Germany | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07176312